This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Congenital neutropenia선천성 호중구감소

ICD-10: D70 | Synonyms: congenital neutropenia, Primary neutropenia, chronic congenital neutropenia

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Early descriptions of congenital neutropenia

The history of congenital neutropenia began in 1956 when Kostmann described severe congenital neutropenia (agranulocytosis). However, congenital neutropenia covers a much broader category than Kostmann syndrome and is a heterogeneous group of diseases with various severities and mechanisms.

Discovery of intermittent neutropenia

From the 1950s, neutropenia recurring in a cycle of about 21 days was observed in certain patient families and described as 'cyclic neutropenia'. Later, in the 2000s, it was found that cyclic neutropenia is caused mainly by autosomal dominant mutations of the ELANE (neutrophil elastase) gene.

Classification of syndromic congenital neutropenia

From the 1970s to the 1990s, various forms of syndromic congenital neutropenia were described, such as Shwachman-Diamond syndrome (exocrine pancreatic insufficiency + neutropenia), myelokathexis (WHIM syndrome), and Cohen syndrome. The molecular basis of each disease was elucidated sequentially from the 1990s–2000s onward.

Contribution of international registry studies

The Severe Chronic Neutropenia International Registry (SCNIR), begun in 1994, accumulated patient data from around the world and provided important information on natural history, the efficacy of G-CSF treatment, and the risk of leukemic transformation.

Recognition in Korea

In Korea, the molecular diagnostic system for congenital neutropenia has been strengthened since the 2000s along with the development of pediatric hematology-oncology. Korean patient cases due to major causative genes such as ELANE and HAX1 have been reported in journals, and a rare disease registry project is under way.

2. Causes

Primary congenital neutropenia

Syndromic congenital neutropenia

SyndromeGene (location)Mode of inheritanceCharacteristic symptoms
Shwachman-Diamond syndrome (SDS)SBDS(7q11.21)ARExocrine pancreatic insufficiency, growth failure, skeletal dysplasia
Myelokathexis/WHIM syndromeCXCR4 (2q22.1) gain of functionADSkin warts, hypogammaglobulinemia, lymphopenia
Cohen syndromeVPS13B(8q22-23)ARIntellectual disability, obesity, characteristic facial features
Barth syndromeTAZ(Xq28)X-linkedCardiomyopathy, muscle weakness, 3-methylglutaconic aciduria
Glycogen storage disease type IbSLC37A4(11q23.3)ARFasting hypoglycemia, hepatomegaly, chronic bowel disease

3. Genetics

Diversity of inheritance patterns

Congenital neutropenia shows various modes of inheritance depending on the disease type. Autosomal dominant (AD): ELANE mutations, CXCR4 gain-of-function mutations. Autosomal recessive (AR): HAX1, G6PC3, SBDS, VPS13B, SLC37A4. X-linked: WAS gain-of-function mutations (XLN), TAZ (Barth syndrome).

Characteristics of the ELANE gene

The ELANE gene (19p13.3) encodes elastase, a serine protease of the primary granules of neutrophils. More than 250 mutations have been reported, and they can cause both severe congenital neutropenia and cyclic neutropenia.

Genetics of Shwachman-Diamond syndrome

SBDS gene mutations cause deficiency of a protein involved in ribosome maturation. Most are compound heterozygous mutations, and the mutations generally arise by gene conversion with the pseudogene (SBDSP).

Genetics of WHIM syndrome

Gain-of-function mutations of the CXCR4 gene (truncation of the C-terminus of CXCR4) cause persistent activation of CXCL12-CXCR4 signaling. As a result, release of mature neutrophils from the bone marrow is inhibited (myelokathexis). It is inherited in an autosomal dominant manner.

4. General epidemiology

Worldwide prevalence

DiseaseEstimated prevalence
Severe congenital neutropenia (SCN)About 1–2/1,000,000
Cyclic neutropeniaAbout 1–2/1,000,000
Shwachman-Diamond syndromeAbout 1/76,000–1/200,000
WHIM syndromeVery rare, fewer than about 100 people worldwide
Cohen syndromeAbout 1/100,000 in Finland

Status in Korea

In Korea, a systematic epidemiological survey covering all congenital neutropenia has not yet been conducted, but data are gradually accumulating in the rare disease registry system. Cases of Shwachman-Diamond syndrome and ELANE mutation-related SCN have been reported in Korean journals.

5. Pathophysiology

Diverse pathogenic mechanisms of congenital neutropenia

Immunodeficiency due to neutropenia

Neutrophils are the first-line defense cells against bacteria and fungi. At ANC <500/uL, the risk of bacterial infection increases markedly, and at ANC <100/uL, the risk of life-threatening infection is very high.

6. Symptoms

Common infection symptoms

Recurrent bacterial infection is the key symptom in all congenital neutropenia. From early life, fever, recurrent pneumonia, skin infections (cellulitis, pyoderma), oral lesions (gingivitis, recurrent stomatitis, early tooth loss), perianal abscesses, lymphadenitis, and sepsis appear.

Disease-specific symptoms

7. Signs

Physical examination findings

Gingivitis and oral ulcers are observed in almost all congenital neutropenia. Failure to thrive and abdominal distension (steatorrhea) in Shwachman-Diamond syndrome. Characteristic facial appearance in Cohen syndrome. Cardiomegaly in Barth syndrome.

Blood test findings

Test itemResult
ANC (severe SCN)<500/uL, <200/uL in severe cases
Cyclic neutropeniaANC fluctuation in a 21-day cycle; nadir <200/uL
WHIM syndromeDecreased ANC + hypersegmented neutrophils on peripheral blood smear
Shwachman-DiamondPossible trilineage cytopenia, low serum amylase/lipase

Bone marrow findings

SCN: maturation arrest at the promyelocyte or myelocyte stage. WHIM syndrome: accumulation of mature neutrophils (myelokathexis), hypersegmented nuclei, reduced granules. Shwachman-Diamond syndrome: hypocellularity, possible trilineage hypoplasia.

8. Screening

Initial screening

In children with recurrent bacterial infections, unexplained fever, oral ulcers, or gingivitis, a CBC is performed first. If ANC <1,500/uL persisting for 3 weeks or more is confirmed, a detailed workup is carried out. When cyclic neutropenia is suspected, CBC 2–3 times a week for 6–8 weeks is performed to confirm a periodic pattern of ANC fluctuation.

Exclusion of autoimmune neutropenia

Autoimmune neutropenia of childhood is excluded by antineutrophil antibody (ANA antibody) testing. Differentiation from autoimmune neutropenia, which usually resolves spontaneously in children aged 18 months to 3 years, is important.

Screening for syndromic features

When Shwachman-Diamond syndrome is suspected, serum pancreatic enzymes (amylase, lipase), fat-soluble vitamins, and steatorrhea testing. When WHIM syndrome is suspected, immunoglobulin quantification and checking for HPV infection.

9. Diagnosis

Bone marrow examination

Bone marrow aspiration and biopsy evaluate the stage of neutrophil maturation, cellularity, and the state of trilineage hematopoiesis.

Molecular genetic testing

An NGS panel for causative genes of congenital neutropenia (including ELANE, HAX1, G6PC3, GFI1, SRP54, SBDS, CXCR4, VPS13B, TAZ, SLC37A4, etc.) is performed. If the panel is negative, whole exome or whole genome sequencing is considered.

Tests specific to Shwachman-Diamond syndrome

Pancreatic exocrine function tests (fecal elastase, serum trypsinogen), abdominal CT/MRI (fatty replacement of the pancreas), SBDS gene analysis, skeletal X-rays (metaphyseal dysplasia).

Tests specific to WHIM syndrome

Confirmation of a CXCR4 gain-of-function mutation, lymphocyte flow cytometry, serum immunoglobulins, HPV serotype testing.

Monitoring for acquired CSF3R mutations

In patients on G-CSF treatment, regular bone marrow examinations and monitoring for mutations such as CSF3R, RAS, and RUNX1 detect transformation to MDS/AML early.

10. Treatment

Granulocyte colony-stimulating factor (G-CSF)

In most congenital neutropenia, G-CSF (filgrastim) is the first-line treatment. Goal: maintain ANC >1,000/uL. The dose is individualized according to disease type and response.

Treatment specific to WHIM syndrome

The CXCR4 antagonist plerixafor (AMD3100) is under clinical study as a targeted therapy that induces release of mature neutrophils from the bone marrow in WHIM syndrome. Low-dose G-CSF and immunoglobulin replacement therapy are used concurrently.

Treatment specific to Shwachman-Diamond syndrome

Pancreatic enzyme replacement therapy (treatment of steatorrhea, improvement of growth failure). Neutrophil support with G-CSF. Hematopoietic stem cell transplantation (HSCT) is considered when bone marrow failure progresses.

Hematopoietic stem cell transplantation (HSCT)

Infection control

Empirical broad-spectrum antibiotics for acute bacterial infections. Prevention and treatment of fungal infections (in some high-risk patients). Vaccination (inactivated vaccines).

11. Prognosis

Prognosis by disease

DiseasePrognosis
SCN(ELANE/HAX1)Infections controlled with G-CSF in most cases. Risk of MDS/AML transformation 10–15% (10 years). Cure possible with successful HSCT.
Cyclic neutropeniaEpisodes controlled with G-CSF. Low risk of AML transformation (about 2%). Relatively favorable.
Shwachman-Diamond syndromeRisk of MDS/AML transformation (about 30% at 20 years). Survival after HSCT about 70–80%.
WHIM syndromeInfection is the main cause of morbidity. Prognosis expected to improve with the introduction of plerixafor.

Need for long-term follow-up

Long-term follow-up is essential for all patients with congenital neutropenia. Regular bone marrow examinations and clonal monitoring, minimizing the G-CSF dose, and early treatment of infections are the keys to improving prognosis.

12. Prevention

Infection prevention

Continuous G-CSF treatment maintains ANC at or above an adequate level. Vaccination (pneumococcal, influenza, meningococcal, varicella). Prophylactic antibiotics (TMP-SMX) if needed. Oral hygiene care to prevent dental infections.

Genetic counseling

Genetic counseling for parents of patients with AR hereditary diseases (HAX1, SBDS, G6PC3, etc.). Prenatal genetic testing (CVS, amniocentesis) or PGT-M can be used.

Monitoring to prevent leukemic transformation

In SCN patients on G-CSF treatment, bone marrow examination 1–2 times a year and monitoring for CSF3R, RUNX1, and RAS mutations. If abnormal clones or MDS findings are detected, G-CSF dose reduction and early consideration of HSCT.

Low-dose G-CSF maintenance

G-CSF is adjusted to the minimum effective dose to minimize the clonal selection pressure associated with high-dose G-CSF use.

13. References

  1. Dale DC, Bolyard AA, Aprikyan A. Cyclic neutropenia. Semin Hematol. 2002;39(2):89-94.
  2. Boztug K, Klein C. Genetics and pathophysiology of severe congenital neutropenia syndromes unrelated to HAX-1. Hematol Oncol Clin North Am. 2013;27(1):43-60.
  3. Burroughs L, Woolfrey A, Shimamura A. Shwachman-Diamond syndrome. Hematol Oncol Clin North Am. 2009;23(2):233-248.
  4. Gulino AV, Moratto D, Sozzani S, et al. Altered leukocyte response to CXCL12 in WHIM syndrome. Blood. 2004;104(2):444-452.
  5. Dale DC, Person RE, Bolyard AA, et al. Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood. 2000;96(7):2317-2322.
  6. Donadieu J, Beaupain B, Fenneteau O, Bellanné-Chantelot C. Congenital neutropenia in the era of genomics. Br J Haematol. 2017;179(4):557-574.
  7. Skokowa J, Dale DC, Touw IP, Zeidler C, Welte K. Severe congenital neutropenias. Nat Rev Dis Primers. 2017;3:17032.
  8. Germeshausen M, Ballmaier M, Welte K. Incidence of CSF3R mutations in severe congenital neutropenia. Blood. 2007;109(2):825-831.
  9. Tamary H, Niss O. Current diagnosis and novel molecular aspects of congenital bone marrow failure syndromes. Eur J Haematol. 2010;84(2):93-108.
  10. Dale DC, Cottle TE, Fier CJ, et al. Severe chronic neutropenia: treatment and follow-up in the SCNIR. Am J Hematol. 2003;72(2):82-93.
  11. Notarangelo LD, Uzel G. Hematopoietic stem cell transplantation for congenital neutropenia. Hematol Oncol Clin North Am. 2009;23(2):371-382.
  12. McDermott DH, Liu Q, Velez D, et al. A phase 1 clinical trial of low-dose treatment of WHIM syndrome with plerixafor. Blood. 2014;123(15):2308-2316.